首页> 外文期刊>Evidence-based complementary and alternative medicine: eCAM >Meta-Analysis of the Effect of Traditional Chinese Medicine Compounds Combined with Standard Western Medicine for the Treatment of Diabetes Mellitus Complicated by Coronary Heart Disease
【24h】

Meta-Analysis of the Effect of Traditional Chinese Medicine Compounds Combined with Standard Western Medicine for the Treatment of Diabetes Mellitus Complicated by Coronary Heart Disease

机译:中药化合物与标准西医结合治疗糖尿病患者复杂化冠心病的荟萃分析

获取原文
           

摘要

This study aimed to systematically evaluate the clinical efficacy and safety of traditional Chinese medicine (TCM) compounds combined with standard treatments for diabetes mellitus (DM) complicated by coronary heart disease (CHD). We performed a systematic and comprehensive search of the China Knowledge Network, WanFang, WeiPu, PubMed, and Web of Science, including Chinese and English articles, for randomized controlled trials (RCTs) assessing the use of Chinese herbal compounds for the treatment of DM complicated by CHD published before June 1, 2020. The literature was screened according to standard criteria. Risk assessment, based on the Jadad scale, was performed using the Review Manager5.3 software for meta-analysis. In total, 23 articles were selected, including 2405 cases. The meta-analysis showed that the combination of standard treatments with TCM compounds significantly improved the overall treatment efficacy for DM complicated by CHD (OR(odds ratio)?=?4.39; 95% confidence interval (95% CI), 3.30–5.84; ), fasting blood glucose level (mean difference (MD)?=??1.04; 95% CI, ?1.96 to ?0.13; ), total cholesterol level (MD?=??1.16; 95% CI, ?1.48 to ?0.83; ), triglyceride (MD?=??0.46; 95% CI, ?0.62 to ?0.29; ), low-density lipoprotein level (MD?=??0.57; 95% CI, ?0.87 to ?0.27; ), high-density lipoprotein level (MD?=?0.19; 95% CI, 0.12 to 0.26; ), and electrocardiogram (OR?=?4.20; 95% CI, 3.15 to 8.18; ). In contrast, there was no improvement of 2-hour postprandial glucose level (MD?=??1.03; 95% CI, ?2.14 to 0.08; ), or adverse reactions (OR?=?0.53; 95% CI, 0.19 to 5.50; ). We concluded that the combined therapy has some benefits in treating DM complicated by CHD. However, these results should be confirmed by further referenced evidence, high risk assessment, and lower publication bias.
机译:该研究旨在系统地评估中药(TCM)化合物的临床疗效和安全性与冠心病(CHD)复杂化的糖尿病(DM)的标准治疗。我们对中国知识网络,万芳,Weipu,PubMed和科学网进行了系统和全面的搜索,包括中式和英语文章,用于随机对照试验(RCT)评估使用中草化合物治疗DM复杂的治疗通过CHD发表于2020年6月1日之前。根据标准标准筛选了文献。基于Jadad Scale的风险评估是使用审查经理5.3软件进行Meta-Analysis进行的。共选出23篇文章,包括2405例。荟萃分析表明,具有TCM化合物的标准处理的组合显着改善了CHD(或(ODDS比)复杂的DM的整体治疗效果(或(差距)?=?4.39; 95%置信区间(95%CI),3.30-5.84; ),禁食血糖水平(平均差异(MD)?= ?? 1.04; 95%CI,?1.96至约0.13;),总胆固醇水平(MD?= ?? 1.16; 95%CI,?1.48至?1.48至0.83 ;),甘油三酯(MD?= 0.46; 95%CI,?0.62至0.29;),低密度脂蛋白水平(MD?= ?? 0.57; 95%CI,?0.87至0.27;),高 - 密度脂蛋白水平(MD?= 0.19; 95%CI,0.12至0.26;)和心电图(或?= 4.20; 95%CI,3.15至8.18;)。相比之下,2小时后葡萄糖水平没有改善(MD?= ?? 1.03; 95%CI,?2.14至0.08;)或不良反应(或?= 0.53; 95%CI,0.19至5.50 ;)。我们得出结论,联合疗法在治疗CHD处理的DM方面具有一些好处。但是,这些结果应通过进一步引用的证据,高风险评估和较低的出版物偏见来确认。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号